St-segment elevation myocardial infarction – Ideal scenario for bioresorbable vascular scaffold implantation?

Circulation Journal

Volumn 79, Issue 2, 2015, Pages 263-270

  Scalone, Giancarla ^a   Brugaletta, Salvatore ^a   Gómez Monterrosas, Omar ^a   Otsuki, Shuji ^a   Sabate, Manel ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Bioresorbable scaffolds; Plaque sealing; ST segment elevation myocardial infarction; Vascular response

Indexed keywords

POLYGLACTIN;

ACUTE CORONARY SYNDROME; ANGIOGRAPHY; ARTICLE; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; BLOOD VESSEL REACTIVITY; CARDIAC IMAGING; DEVICE SAFETY; DRUG ELUTING STENT; EVENT FREE SURVIVAL; EVEROLIMUS ELUTING STENT; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; INTRACORONARY IMAGING; LEFT ANTERIOR DESCENDING CORONARY ARTERY; METAL STENT; MULTICENTER STUDY (TOPIC); NEOINTIMA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBECTOMY; VASCULAR PATENCY; BIODEGRADABLE IMPLANT; BIOPROSTHESIS; BLOOD VESSEL PROSTHESIS; MYOCARDIAL INFARCTION;

ABSORBABLE IMPLANTS; BIOPROSTHESIS; BLOOD VESSEL PROSTHESIS; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84928233432     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-1398     Document Type: Article

References (69)

1. Authors/Task Force members; Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541–2619.
2. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093–1104.
3. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360: 1946–1959.
4. Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, et al. Use of drug-eluting stents in acute myocardial infarction: A systematic review and meta-analysis. J Am Coll Cardiol 2009; 53: 1677–1689.
5. Karanasos A, Ligthart J, Witberg K. Association of neointimal morphology by optical coherence tomography with rupture of neoatherosclerotic plaque very late after coronary stent implantation. Proc SPIE 8565, Photonic Therapeutics and Diagnostics IX, 856542 (March 8, 2013), doi:10.1117/12.2006331.
6. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435–2441.
7. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193–202.
8. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by denovo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015; 385: 43–54.
9. Räber L, Kelbæk H, Ostojic M, Baumbach A, Heg D, Tüller D, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: The COMFORTABLE AMI randomized trial. JAMA 2012; 308: 777–787.
10. Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Hernádez-Antolín R, et al. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. JACC Cardiovasc Interv 2014; 7: 64–71.
11. Sabaté M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380: 1482–1490.
12. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Smots PC, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: Evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013; 62: 496–504.
13. Scalone G, Brugaletta S, Gomez O, Otsuki S, Sabate M. Bioresorbable scaffolds: Focus on vascular response and long-term safety. Panminerva Med 2014 November 6 [Epub ahead of print].
14. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, et al. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation 2004; 109: 881–886.
15. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, et al. Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113: 414–419.
16. Gomez O, Regueiro A, Santos A, Otsuki S, Scalone G, Fernández-Rodríguez D, et al. Recanalized thrombus treated with bioresorbable vascular scaffold: Insights from optical coherence tomography. JACC Cardiovasc Interv 2014; 7: 1453–1455.
17. Vorpahl M, Nakano M, Perkins LE, Otsuka F, Jones R, Acampado E, et al. Vascular healing and integration of a fully bioresorbable everolimus-eluting scaffold in a rabbit iliac arterial model. EuroIntervention 2014; 10: 833–841.
18. Vorpahl M, Finn AV, Nakano M, Virmani R. The bioabsorption process: Tissue and cellular mechanisms and outcomes. EuroIntervention 2009; 5(Suppl F): F28–F35.
19. Gogas BD, Radu M, Onuma Y, Perkins L, Powers JC, Gomez-Lara J, et al. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: Implications of pilot results for future pre-clinical studies. Int J Cardiovasc Imaging 2012; 28: 499–511.
20. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, GarciaGarcia HM, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: An attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010; 122: 2288–2300.
21. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58: 1578–1588.
22. Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: Indirect finding of vascular reparative therapy? Eur Heart J 2012; 33: 1325–1333.
23. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–1323.
24. Shin DI, Kim PJ, Seung KB, Kim DB, Kim MJ, Chang K, et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 2007; 48: 553–567.
25. Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque? Atherosclerosis 2012; 221: 106–112.
26. Bourantas CV, Papafaklis MI, Kotsia A, Farooq V, Muramatsu T, Gomez-Lara J, et al. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: An optical coherence tomography study. JACC Cardiovasc Interv 2014; 7: 315–324.
27. Bourantas CV, Serruys PW, Nakatani S, Zhang YJ, Farooq V, Diletti R, et al. Bioresorbable vascular scaffold treatment induces the formation of neointimal capthat seals the underlying plaque without compromising the luminal dimensions: A concept based on serial optical coherence tomography data. EuroIntervention 2014 October 14, doi:10.4244/EIJY14M10_06.
28. Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire R, Dijkstra J, et al. OCT Assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol 2014; 64: 2343–2356.
29. Cortese B, Valgimigli M. Current know how on the absorb BVS technology: An experts’ survey. Int J Cardiol 2014; 180C: 203–205.
30. Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention 2013; 9: 501–504.
31. Wiebe J, Möllmann H, Most A, Dörr O, Weipert K, Rixe J, et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting biore-sorbable vascular scaffold. Clin Res Cardiol 2014; 103: 141–148.
32. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J 2014; 35: 777–786.
33. Kočka V, Malý M, Toušek P, Buděšínský T, Lisa L, Prodanov P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: A prospective multicentre study ‘Prague 19’. Eur Heart J 2014; 35: 787–794.
34. Rzeszutko Ł, Siudak Z, Włodarczak A, Lekston A, Depukat R, Ochała A, et al. Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry. Kardiol Pol 2014; 72: 1394–1399.
35. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2014; 9: 1036–1041.
36. Kochman J, Tomaniak M, Pietrasik A, Kołtowski L, Rdzanek A, Huczek Z, et al. Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes. Cardiol J 2014 November 27, doi:10.5603/CJ.a2014.0090.
37. Ielasi A, Cortese B, Varricchio A, Tespili M, Sesana M, Pisano F, et al. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre “Registro ABSORB Italiano” (RAI registry). EuroIntervention 2014 October 30, doi:10.4244/EIJY14M10_11.
38. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, et al. Aborb bioresorbable scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a Propensity Score matching comparison: The BVS-EXAMINATION (bioresorbable Vascular Scaffold-Everolimus-Eluting Stent Versus Bare-Metal Stent in ST-Segment Elevation Myocardial Infarction) Study. JACC Cardiovasc Interv 2015 (in press).
39. Serruys PW, Sabaté M, Windecker S. Comparison of the ABSORBTM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug-Eluting Metal Stent (XienceTM) in Acute ST-Elevation Myocardial Infarction. NCT01986803.
40. Simsek C, Magro M, Onuma Y, Boersma E, Smits P, Dorange C, et al. Procedural and clinical outcomes of the Absorb everolimuseluting bioresorbable vascular scaffold: One-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH). EuroIntervention 2013; 10: 236–240.
41. Fernández-Rodríguez D, Brugaletta S, Otsuki S, Sabaté M. Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: To stent or not to stent? EuroIntervention 2014; 10: 600.
42. Van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis: The dutch stent thrombosis registry. J Am Coll Cardiol 2009; 53: 1399–1409.
43. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2014 July 18, doi:10.4244/EIJY14M07_11.
44. Onuma Y, Ormiston J, Serruys PW. Bioresorbable scaffold technologies. Circ J 2011; 75: 509–520.
45. Brown AJ, McCormick LM, Braganza DM, Bennett MR, Hoole SP, West NE. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv 2014; 84: 37–45.
46. Görge G, Haude M, Ge J, Gerber T, Rupprecht HJ, Meyer J, et al. Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation. J Am Coll Cardiol 1995; 26: 725–730.
47. Hur SH, Kitamura K, Morino Y, Honda Y, Jones M, Korr KS, et al. Efficacy of postdeployment balloon dilatation for current generation stents as assessed by intravascular ultrasound. Am J Cardiol 2001; 88: 1114–1119.
48. Doi H, Maehara A, Mintz GS, Yu A, Wang H, Mandinov L, et al. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: An integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv 2009; 2: 1269–1275.
49. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, et al; SIRIUS Investigators. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 2004; 43: 1959–1963.
50. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: An intravascular ultrasound study. J Am Coll Cardiol 2005; 45: 995–998.
51. Costopoulos C, Latib A, Naganuma T, Miyazaki T, Sato K, Figini F, et al. Comparison of early clinical outcomes between absorb bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real- world population. Catheter Cardiovasc Interv 2015; 85: E10–E15.
52. Mattesini A, Secco GG, Dall’Ara G, Ghione M, Rama-Merchan JC, Lupi A, et al. ABSORB biodegradable stents versus second- generation metal stents: A comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv 2014; 7: 741–750.
53. Latib A, Ferri L, Ielasi A, Godino C, Chieffo A, Magni V, et al. Clinical outcomes after unrestricted implantation of everolimuseluting stents. JACC Cardiovasc Interv 2009; 2: 1219–1226.
54. Chieffo A, Latib A, Caussin C, Presbitero P, Galli S, Menozzi A, et al. A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial. Am Heart J 2013; 165: 65–72.
55. Roy P, Steinberg DH, Sushinsky SJ, Okabe T, Pinto Slottow TL, Kaneshige K, et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J 2008; 29: 1851–1857.
56. Claessen BE, Mehran R, Mintz GS, Weisz G, Leon MB, Dogan O, et al. Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents. JACC Cardiovasc Interv 2011; 4: 974–981.
57. Park SJ, Kim YH, Park DW, Lee SW, Kim WJ, Suh J, et al; MAIN-COMPARE Investigators. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. Circ Cardiovasc Interv 2009; 2: 167–177.
58. Mudra H, di Mario C, de Jaegere P, Figulla HR, Macaya C, Zahn R, et al; OPTICUS (OPTimization with ICUS to reduce stent restenosis) Study Investigators. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). Circulation 2001; 104: 1343–1349.
59. Oemrawsingh PV, Mintz GS, Schalij MJ, Zwinderman AH, Jukema JW, van der Wall EE; TULIP Study. Thrombocyte activity evaluation and effects of Ultrasound guidance in Long Intracoronary stent Placement. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: Final results of a randomized comparison with angiographic guidance (TULIP Study). Circulation 2003; 107: 62–67.
60. Prati F, Di Vito L, Biondi-Zoccai G, Occhipinti M, La Manna A, Tamburino C, et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: The Centro per la Lotta contro l’Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. EuroIntervention 2012; 8: 823–829.
61. Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, et al. Assessment of culprit lesion morphology in acute myocardial infarction: Ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 2007; 50: 933–939.
62. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: A multi-imaging modality study. Circ Cardiovasc Interv 2012; 5: 620–632.
63. Garcia-Garcia HM, Serruys PW, Campos CM, Muramatsu T, Nakatani S, Zhang YJ, et al. Assessing bioresorbable coronary devices: Methods and parameters. JACC Cardiovasc Imaging 2014; 7: 1130–1148.
64. Gomez-Lara J, Diletti R, Brugaletta S, Onuma Y, Farooq V, Thuesen L, et al. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: An ABSORB cohort B trial sub-study. EuroIntervention 2012; 8: 214–224.
65. Kraak RP, Hassell ME, Grundeken MJ, Koch KT, Henriques JP, Piek JJ, et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: The AMC Single Centre Real World PCI Registry. EuroIntervention 2014 August 20, doi:10.4244/EIJY14M08_08.
66. Allahwala UK, Cockburn JA, Shaw E, Figtree GA, Hansen PS, Bhindi R. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention. EuroIntervention 2014 March 20 [Epub ahead of print].
67. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007; 70: 515–523.
68. Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, et al; ABSORB Cohort A and B investigators. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011; 78: 3–12.
69. Ishibashi Y, Onuma Y, Muramatsu T, Nakatani S, Iqbal J, GarciaGarcia HM, et al; ABSORB EXTEND Investigators. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention 2014; 10: 449–457.